

Date: 14th November, 2022

To,
Listing Compliance Department
National Stock Exchange of India Limited,
Exchange Plaza, C-1, Block G,
BandraKurla Complex,
Bandra (E), Mumbai – 400051

Ref: MK Proteins Limited (Scrip Code/Symbol - MKPL, INE964W01013)

Subject: Outcome of Board Meeting of the Company held on 14th November, 2022 pursuant to Regulation 30 and 33 of SEBI (Listing Obligation & Disclosure Requirements), Regulations 2015.

Dear Sir/Madam,

In terms of Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors of the Company in their meeting held today i.e 14th November, 2022 at the Registered Office of the Company, subject to member's approval and other statutory approvals, *inter-alia* considered and approved the following:

- Unaudited Financial Results for the Half Year ended 30th September, 2022 along with Auditors Limited Review Reports for the Half Year ended 30th September, 2022.
- Increase in Authorized Share Capital of the Company from Rs. 5,00,00,000 (Rupees Five Crore Only) to Rs. 15,00,00,000 (Rupees Fifteen Crore Only) and consequent alteration in Clause V (Capital Clause) of Memorandum of Association of the Company, subject to the approval of shareholders through Postal Ballot as per section 110 of the Companies Act, 2013.
- Recommended the Bonus Issue of Equity Shares in the proportion of 2:1 i.e. 2 (Two) fully paid-up Bonus Equity Share of Rs. 10/- each for every 1 (One) existing Equity Share, held by each shareholder as on the record date, subject to the approval of shareholders through Postal Ballot i.e. in compliance with the applicable laws;
- 4. Migration of the company from NSE SME Platform to NSE's Main Board
- Listing the Company on Main Board of BSE Limited's subject to the approval of Stock Exchanges and the shareholders through postal ballot as per section 110 of the Companies Act, 2013

M. K. Proteins Limited



- Change in designation of Mr. Parmod Kumar (DIN: 00126965) from Director to Managing Director of the Company, subject to the approval of shareholders through Postal Ballot
- 7. Change in designation of Mr. Vinod Kumar (DIN: 00150507) from Managing Director to Whole Time Director of the Company, subject to the approval of shareholders through Postal Ballot
- Change in designation of Mr. Raj Kumar (DIN: 00126983) from Whole Time Director to Director of the Company, subject to the approval of shareholders through Postal Ballot
- 9. Issue of Postal Ballot Notice and other incidental matters thereto:

To seek requisite member's approval for abovesaid items, wherever necessary, by way of passing resolutions through Postal Ballot process being initiated separately.

The Postal Ballot Notice will be sent to the members electronically on the email ID's registered by them with the Depository participant(s)/ the company and whose names appear in the List of Beneficial Owners as furnished by the NSDL and CDSL as on the close of business hours on Friday, the November 11, 2022 being the cut-off date.

10. Appointment of Sh J P Jagdev, Company Secretaries, Ambala, as Scrutinizer to conduct Postal Ballot process and E voting in fair and transparent manner.

The meeting of board of directors commenced at P.M. and concluded at PM

You are requested to take the information on record and oblige.

Thanking You,

Yours Truly,

For M K Proteins Limited

VINOD KUMAR Managing Director DIN: 00150507

M. K. Proteins Limited

Naraingarh Road, Village Garnala, Ambala City(Haryana), India - 134003 T: 0171-2679358 | W: www.mkproteins.in | E: mkproteins1@gmail.com | info@mkproteins.in

TIN: 06291043467 CIN: L15500HR2012PLC046239

(Formerly Known as M. K. Proteins Private Limited)

Regd. Office: Naraingarh Road, Village Garnala, Ambala City (Haryana), India - 134003 T: 0171-2679358 | W: www.mkproteins.in | E: info@mkproteins.in

TIN: 06291043467 CIN: U15500HR2012PLC046239

Dated: 14th November, 2022

To,

The General Manager, Listing Department, NSE Limited-SME Platform Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E) Mumbai – 400051

Ref: MKPL

Sub: Unaudited Standalone Financial Results for the half-year ended September 30, 2022

Sir,

We wish to inform you that the Board of Directors of the company has approved the unaudited standalone financial results for the half-year ended September 30, 2022 pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") in their meeting held on 14th November, 2022. We enclose the following:

a) Statement showing the unaudited standalone Financial Results for the half-year ended 30th September 2022.

b) Independent Limited Review Report on unaudited Standalone Financial Results for the half-year ended 30th September 2022.

A copy of the same will be updated on the Company's Website.

Kindly take the information on record.

Thanking you, Yours faithfully,

For M. K. Proteins Limited

(WNOD KUMAR)

Managing Director DIN: 00150507

(Formerly Known as M. K. Proteins Private Limited)
Regd. Office: Naraingarh Road, Village Garnala, Ambala City (Haryana), India - 134003 T: 0171-2679358 | W: www.mkproteins.in | E: info@mkproteins.in

TIN: 06291043467 CIN: U15500HR2012PLC046239

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE HALF YEAR ENDED 30TH **SEPTEMBER 2022**

(Rs. In Lacs)

		HALF YEAR ENDED			YEAR ENDED		
		30-09-2022 (UNAUDITED)	31-03-2022 (AUDITED)	30-09-2021 (UNAUDITED)	31-03-2022 (AUDITED)	31-03-2021 (AUDITED)	
	Revenue		*				
a)	Net Sales/Income from Operations	13950.53	14270.85	11317.99	25588.84	31109.79	
	Other operating Revenue	0.00	0.03	0.00	0.03	0.00	
	Revenue from Operation (Net)	13950.53	14270.88	11317.99	25588.87	31109.79	
b)	Other Income	2.06	4.78	8.90	13.68	4.80	
	Sub-Total "1"	13952.59	14275.66	11326.89	25602.55	31114.59	
	Expenditure						
a)	Cost of Material Consumed	9630.80	13509.20	6130.11	19639.31	22117.73	
b)	Purchase of Stock-in-Trade	2723.74	337.55	3966.53	4304.08	5560.78	
c)	Change in inventories of Finished Goods, Work-in-progress and Stock-in-Trade	421.19	(1264.19)	33.35	(1230.84)	900.90	
d)	Employees Benefits Expenses	92.73	102.92	78.66	181.58	154.71	
e)	Manufacturing, Operating and Other Expenses	477.23	783.60	346.03	1129.63	782.39	
f)	Finance Costs	69.43	56.64	26.61	83.25	74.98	
g)	Depreciation and Amortization Expenses	37.97	47.06	44.26	91.32	90.94	
	Sub-Total "2"	13453.09	13572.78	10625.55	24198.33	29682.43	
	Profit/(Loss) before Exceptional, Extraordinary items and Tax [1-2]	499.50	702.88	701.34	1404.22	1432.16	
	Exceptional Items	0.00	0.00	0.00	0.00	0.00	
5	Profit/(Loss) before Extraordinary items and Tax [3-4]	499.50	702.88	701.34	1404.22	1432.16	
	Extraordinary Items	0.00	0.00	0.00	0.00	0.00	
7	Profit/(Loss) before Tax [5-6]	499.50	702.88	701.34	1404.22	1432.16	
8	Tax Expenses						
a)	Provision for Current Tax	127.99	207.76	180.36	388.12	402.32	
b)	Provision for Deferred Tax Liability/(Adjustment)	(1.59)	1.45	(3.80)	(2.35)	(9.05)	
	Sub-Total "8"	126.40	209.21	176.56	385.77	393.27	
9	Profit/(Loss) for the Period from continuing operations [7-8]	373.10	493.67	524.78	1018.45	1038.89	
	Profit/(Loss) for the period from Discontinuing operations	0.00	0.00	0.00	0.00	0.00	
11	Tax expenses of Discontinuing operations	0.00	0.00	0.00	0.00	0.00	
	Profit/(Loss) from Discontinuing operations (After Tax) [10 – 11]	0.00	0.00	0.00	0.00	0.00	
13	Profit/(Loss) for the period [9 + 12]	373.10	493.67	524.78	1018.45	1038.89	
	Earning Per Shares [EPS]						
	-Basic	8.95	11.84	12.58	24.42	24.91	
	-Diluted	8.95	11.84	12.58	24.42	24.91	
15	Paid-up Equity Shares Capital						
	4170800 (Previous year 2708800) Equity	417.08	417.08	417.08	417.08	417.08	
	Shares (Face value of Share Rs.10/- each)	(Rs.10/- each)	(Rs.10/- each)	(Rs.10/- each)	(Rs.10/- each)	(Rs.10/- each)	
16	Reserves excluding Revaluation Reserves	3916.44	3543.30	3041.54	3543.30	2516.76	

Note:

1. The above mentioned audited results were reviewed by the Audit Committee and approved by the Board of Directors of the Company at its meeting held on 14th November, 2022.

Previous year figures have been regrouped / rearranged, wherever necessary, to confirm with the current period classification.

The Company is engaged in single business activity (i.e. Manufacturing of Vegetable Refined oil) and there is no separate

The Company has taken into account all the possible impacts of COVID-19 in preparation of standalone financial statements, including but not limited to its assessment of, liquidity and going concern assumption and recoverable values of its financial and non-financial assets. The Company has carried out this assessment based on available internal and external sources of information up to the date of approval of standalone financial statements and believes that the impact of COVID-19 is not material to these financial statements and expects to recover the carrying amount of its assets. The impact of COVID-19 on the standalone financial statements may differ from that estimated as at the date of approval of these standalone financial statements owing to the nature and duration of COVID-19.

5. Disclosure of assets and liabilities as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements)

Regulations, 2015 for the half year ended 30th September, 2022 is given as per Annexure "I" attached

Place: Ambala

Dated: 14-11-2022

For and on behalf of the board

(Vinod Kumar) **Managing Director** DIN: 00150507

(Formerly Known as M. K. Proteins Private Limited)
Regd. Office: Naraingarh Road, Village Garnala, Ambala City (Haryana), India - 134003

T: 0171-2679358 | W: www.mkproteins.in | E: info@mkproteins.in

TIN: 06291043467 CIN: U15500HR2012PLC046239

ANNEXURE "I"

STATEMENT OF ASSETS AND LIABILITIES AS AT 30TH SEPTEMBER 2022 IS GIVEN BELOW: -

	PARTICULARS	AS AT 30-09-2022 (UNAUDITED)	AS AT 30-09-2021 (UNAUDITED)	AS AT 31-03-2022 (AUDITED)
A	EQUITY AND LIABILITIES			
1	Shareholder's Funds		117.00	417.00
	-Share Capital	417.08	417.08	417.08
	-Reserves and Surplus	3916.44	3041.54	3543.30
	Sub-Total - Shareholder's Funds	4333.52	3458.62	3960.38
2.	Non-Current Liabilities			247.20
	-Long Term Borrowings	222.35	21.81	265.39
	-Deferred Tax Liabilities (Net)	0.00	0.00	0.00
	-Other Long Term Liabilities	0.00	0.00	0.00
	-Long Term Provisions	7.73	5.56	7.73
	Sub-Total - Non-Current Liabilities	230.08	27.37	273.12
3.	Current Liabilities			2412.04
	-Short Term Borrowings	818.35	0.00	3413.04
	-Trade Payables	429.88	743.74	503.14
	-Other Current Liabilities	32.24	131.10	76.98
	-Short Term Provisions	369.40	196.04	388.12
	Sub-Total – Current Liabilities	1649.87	1070.88	4381.28
	Total Equity And Liabilities	6213.47	4556.87	8614.78
В.	ASSETS			
1.	Non-Current Assets		257.46	211.01
	-Property, Plant and Equipment	273.04	257.46	311.01 30.02
	-Deferred Tax Assets (Net)	31.61	31.48	
	-Long Term Loans and Advances	0.00	42.35	0.00 42.35
	-Other Non-Current Assets	42.35	0.00	
	Sub-Total - Non-Current Assets	347.00	331.29	383.38
2.	Current Assets			0.00
	-Current Investment	0.00	930.00	0.00
	-Inventories	2978.50	989.80	4976.81
	-Trade Receivables	2736.04	2165.32	2920.89
	-Cash and Bank Balances	6.10	2.21	0.67
	-Short Term Loan and Advances	145.83	138.07	333.03
	-Other Current Assets	0.00	0.18	0.00
	Sub-Total – Current Assets	5866.47	4225.58	8231.40
	Total Assets	6213.47	4556.87	8614.78

Place: Ambala

Dated: 14-11-2022

For and on behalf of the board

(Vinod Kumar) Managing Director DIN: 00150507

(Formerly Known as M. K. Proteins Private Limited)
Regd. Office: Naraingarh Road, Village Garnala, Ambala City (Haryana), India - 134003 T: 0171-2679358 | W: www.mkproteins.in | E: info@mkproteins.in

CIN: U15500HR2012PLC046239

CASH FLOW STATEMENT FOR THE HALF YEAR ENDED 30TH SEPTEMBER 2022

PARTICULARS	30/09/2022 (Rs.)	30/09/2021 (Rs.)	31/03/2022 (Rs.)
A. CASH INFLOW/(OUTFLOW) FROM OPERATING ACTIVITIES			
Net Profit/(Loss) before tax	499.50	701.34	1404.21
Adjustment for: -			
-Depreciation	37.97	44.26	91.32
-Interest paid	69.43	26.61	83.25
-Provision for Doubtful debts	0.00	0.00	(18.53)
-Provision for Retirement Gratuity Benefit to Employees	0.00	0.00	2.17
-Preliminary Expenses Written off	0.00	0.00	0.18
-Interest Income	(1.16)	(1.59)	(2.86)
-Profit on sale of Mutual Fund Investment	(0.90)	(1.60)	(4.99)
-(Profit)/Loss on Sale of Assets	0.00	0.00	0.00
Operating profit before working capital changes	604.84	769.02	1554.75
Adjustment for changes in working capital: -			
-Increase/(decrease) in Trade and other Payables	(117.99)	(15.94)	(297.19)
-(Increase)/decrease in Trade Receivables	184.85	(99.96)	(837.00)
-(Increase)/decrease in Inventories	1998.31	2780.13	(1206.87)
-(Increase)/decrease in Loans and Advances	109.13	350.03	251.62
Cash generated from operations	2779.14	3783.28	(534.69)
(i) Income Tax paid	(68.60)	(290.16)	(394.30)
(ii) Interest paid	(69.43)	(26.61)	(83.25)
(iii) Dividend paid	0.00	0.00	0.00
Net Cash inflow/(outflow) from operating activities (A)	2641.11	3466.51	(1012.24)
B. CASH INFLOW/(OUTFLOW) FROM INVESTING ACTIVITIES			
-Sale Proceeds of fixed assets/Subsidy Received	0.00	0.00	0.00
-Sale Proceeds for Investment in Mutual Funds -Increase in Tangible and Intangible Assets (Including Capital	455.90	1091.60	2024.99
work-in-progress)	0.00	(56.62)	(157.22)
-Investment in Mutual Funds and others	(455.00)	(2020.00)	(2020.00)
-Sundry Creditors for Capital goods	0.00	0.00	(3.42)
-Interest Income	1.16	1.59	2.86
-(Increase)/decrease in Long Term Advances & Other Non Current Assets	0.00	0.00	0.00
Net Cash Inflow/(Outflow) from investing activities (B)	2.06	(983.43)	(152.79)

C. CASH INFLOW/(OUTFLOW) FROM FINANCING ACTIVITIES -Increase/(decrease) in short term bank borrowings (i.e. cash credit and overdraft facilities)	(2622.62)	(2011 20)	1201 22
	(2632.62)	(2011.30)	1391.32
-Proceeds from long/short term bank and other Long term funds	0.00	34.47	284.73
-Repayment of Long Term Fund (Tem Loans and other Unsecured Loans)	(5.12)	(504.17)	(510.48)
-Proceeds from issue of share capital	0.00	0.00	0.00
Net Cash inflow/(outflow) from financing activities (C)	(2637.74)	(2481.00)	1165.57
Net Cash flow during the year (A+B+C)	5.43	2.08	0.54
Cash and Cash Equivalent (Opening Balance)	0.67	0.13	0.13
Cash and Cash Equivalent (Closing Balance)	6.10	2.21	0.67

Place: Ambala

Dated: 14-11-2022

For and on behalf of the board

(Vinod Kumar) Managing Director DIN: 00150507

PARAMPREET KHURANA & ASSOCIATES

CHARTERED ACCOUNTANTS



Limited Review Report on unaudited Standalone Half Yearly Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015

To

The Board of Directors,
M. K. Proteins limited
Naraingarh Road, Village Garnala,
Ambala City (Haryana), India - 134003

Ref: Limited Review Report of unaudited Standalone financial Results For the half year ended 30th September, 2022

- 1. We have reviewed the accompanying statement of unaudited half yearly standalone financial results of M. K. Proteins Limited (Formerly Known as M. K. Proteins Private Limited) ("the Company") for the half year ended September 30, 2022, attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. These half yearly standalone financial results have been prepared on the basis of the standalone financial statements for the half year ended September 30, 2022, which are the responsibility of the Company's management and have been prepared in accordance with the recognition and measurement principles laid down in Accounting Standards prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India, and the relevant requirements of the Regulations and has been approved by the Board of Directors. Our responsibility is to issue a report on this Financial Statement based on our review.
- 2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim financial information performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
- 3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited half yearly Financial Results, prepared in accordance with applicable accounting standards specified under section 133 of the Companies Act, 2013 read with rule 7 of the Companies (Accounts) Rules, 2014, and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 05, 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Emphasis of Other Matters

We draw attention to Note 4 of the standalone financial results, as regards the management's evaluation of COVID-19 impact on the business operations and carrying amounts of financial and non-financial assets of the Company. Our opinion is not modified in respect of this matter.

FOR PARAMPREET KHURANA & ASSOCIATES CHARTERED ACCOUNTANTS

FRN: 030838 N

PARAMPRREET KHURANNA

PROPREITOR M. No 534706 Date: 14th November, 2022 PLACE: CHANDIGARH UDIN: 22534706BDCPVN7145



Annexure-A

DETAILS UNDER REGULATION 30 OF SECURITIES AND EXCHANGE BOARD OF INDIA (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015

Sr. No.	Particulars	Details
NO.		
1	Type of securities proposed to be issued	Equity Shares
2	Type of issuance	Bonus Issue
3	Total number of securities proposed to be issued or the total amount for which the securities will be issued (approximately)	Rs. 8,34,16,000/- divided into 83,41,600 Equity Shares of face value of Rs. 10/- each.
4	Whether bonus is out of free reserves created out of profits or share premium account	Bonus shares will be issued out of Free Reserves created out of profits of the Company available as at March 31, 2022.
5	Bonus ratio	2 (Two) Equity Shares of Rs 10/- each for every 1 (One) existing Equity Share of Rs.10/- each held as on a record date.
6	Details of share capital - pre and post bonus issue	Pre-Bonus paid-up share capital: Rs. 4,17,08,000/- divided into 41,70,800 Equity Shares of face value of Rs. 10/- each. Post-Bonus paid-up share capital: Rs. 12,51,24,000/- divided into 1,25,12,400
		Equity Shares of face value of Rs. 10/- each.
7	Free reserves and/ or share premium required for implementing the bonus issue	Free Reserves of Rs. 8,34,16,000/- are required for implementing the Bonus Issue.

M. K. Proteins Limited

Naraingarh Road, Village Garnala, Ambala City(Haryana), India - 134003

T: 0171-2679358 I W: www.mkproteins.in I E: mkproteins1@gmail.com I info@mkproteins.in

TIN: 06291043467 CIN: L15500HR2012PLC046239



M K PROTEINS

available for capitalization an	Free reserves and/ or share premium available for capitalization and the date as on which such balance is	As on March 31, 2022, the balance available in Free Reserves and Securities Premium is as under:
	available	Free Reserves: 27,07,92,733.68/-
		Security Premium: 8,35,37,361/-
	Table 20 miles	The above figures as per the Audited Balance Sheet as on 31st March, 2022
9	Whether the aforesaid figures are audited	Yes
10	Estimated date by which such bonus shares would be credited/ dispatched	Within 2 months from the date of Board approval i.e by January 14, 2023

For M K Proteins Limited

VINOD KUMAR Managing Director DIN: 00150507